CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CytomX Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CytomX Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Carvajal Alejandra | Chief Legal Officer | 100,000 | Aug 5, 2026 | 1 |
| Fuchs Charles S. | Director | – | Jul 30, 2026 | 1 |
| Jones Elaine V | Director | 5,142 | Jun 22, 2026 | 1 |
| Meyers James R | Director | – | Jun 22, 2026 | 1 |
| Gilbert Halley E | Director | – | Jun 22, 2026 | 1 |
| Young Matthew P. | Director | – | Jun 22, 2026 | 1 |
| Mohindru Mani | Director | – | Jun 22, 2026 | 1 |
| Ashworth Alan | Director | – | Jun 22, 2026 | 1 |
| Su Zhen | Director | – | Jun 22, 2026 | 1 |
| Ogden Christopher | Chief Financial Officer | 295,324 | Jun 17, 2026 | 4 |
| McCarthy Sean A. | CEO | 1,078,922 | Mar 19, 2026 | 4 |
| Chu Yu-Waye | Chief Medical Officer | 189,446 | Mar 19, 2026 | 3 |
| Belvin Marcia | SVP, Chief Scientific Officer | 300,760 | Mar 19, 2026 | 3 |
| Lester Rachael | Chief Business Officer | 20,000 | Feb 4, 2026 | 2 |
| Rowland Lloyd A | General Counsel | 120,594 | Mar 20, 2025 | 0 |
| Landau Jeffrey B | Chief Business Officer | 119,056 | Aug 22, 2024 | 0 |
| Peterson Amy C. | EVP, Chief Development Officer | 58,433 | Mar 20, 2023 | 0 |
| Campoy Carlos | Chief Financial Officer | 38,224 | Mar 20, 2023 | 0 |
| Hannah Alison L. | Chief Medical Officer | 31,898 | Jul 21, 2022 | 0 |
| Gluck Frederick W | Director | – | Jun 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Ogden ChristopherChief Financial Officer | SSale | −1.62K | $3.05 | −$4.95K | −0.5%295.3K after | |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Chu Yu-WayeChief Medical Officer | SSale | −21.3K | $6.42 | −$136.6K | −10.1%189.4K after | |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | McCarthy Sean A.CEO | SSale | −119.0K | $6.42 | −$763.8K | −9.9%1.08M after | 10b5-1 |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Belvin MarciaSVP, Chief Scientific Officer | SSale | −31.5K | $6.42 | −$202.2K | −9.5%300.8K after | |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Ogden ChristopherChief Financial Officer | SSale | −19.3K | $6.42 | −$124.1K | −6.1%296.9K after | |
| Nov 10, 2025 (view filing) | Nov 6 | 4 days | McCarthy Sean A.CEO | SSaleClass A Common Stock | −101.8K | $4.54 | −$462.1K | −9.3%987.9K after | 10b5-1 |
| Jun 17, 2025 (view filing) | Jun 13-16 | 4 days | Ogden ChristopherChief Financial Officer | SSale | −12.3K | $2.72 | −$33.4K | −5.1%226.3K after | 2 lots |
| Jun 17, 2025 (view filing) | Jun 16 | 1 day | Belvin MarciaSVP, Chief Scientific Officer | SSale | −13.9K | $2.69 | −$37.3K | −4.9%272.3K after | |
| Jun 17, 2025 (view filing) | Jun 16 | 1 day | McCarthy Sean A.CEO | SSale | −55.5K | $2.69 | −$149.3K | −4.8%1.09M after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | McCarthy Sean A.CEO | SSale | −37.7K | $0.60 | −$22.6K | −3.6%995.2K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Ogden ChristopherChief Financial Officer | SSale | −8.55K | $0.60 | −$5.13K | −4.1%201.0K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Chu Yu-WayeChief Medical Officer | SSale | −4.03K | $0.60 | −$2.42K | −2.9%135.7K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Rowland Lloyd AGeneral Counsel | SSale | −10.2K | $0.60 | −$6.12K | −7.8%120.6K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Belvin MarciaSVP, Chief Scientific Officer | SSale | −19.5K | $0.60 | −$11.7K | −7.3%248.6K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Landau Jeffrey BChief Business Officer | SSale | −4.18K | $1.23 | −$5.14K | −3.4%119.1K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Belvin MarciaSVP, Chief Scientific Officer | SSale | −4.18K | $1.23 | −$5.14K | −2.3%175.6K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Rowland Lloyd AGeneral Counsel | SSale | −4.18K | $1.23 | −$5.14K | −3.1%130.8K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Ogden ChristopherChief Financial Officer | SSale | −1.98K | $1.23 | −$2.44K | −1.8%108.1K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | McCarthy Sean A.CEO | SSale | −13.9K | $1.23 | −$17.1K | −2.1%657.9K after | |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Rowland Lloyd AGeneral Counsel | SSale | −5.27K | $2.09 | −$11.0K | −4.3%117.7K after | |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | McCarthy Sean A.CEO | SSale | −20.2K | $2.09 | −$42.3K | −3.7%524.5K after | |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Ogden ChristopherSVP, Finance and Accounting | SSale | −2.97K | $2.09 | −$6.21K | −3.4%85.7K after | |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Belvin MarciaSVP, Chief Scientific Officer | SSale | −12.8K | $2.09 | −$26.7K | −7.1%168.6K after | |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Landau Jeffrey BChief Business Officer | SSale | −6.56K | $2.09 | −$13.7K | −5.6%110.1K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | McCarthy Sean A.CEO | SSale | −13.6K | $1.38 | −$18.7K | −2.9%454.7K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Belvin MarciaSVP, Chief Scientific Officer | SSale | −4.08K | $1.38 | −$5.63K | −2.6%155.1K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Landau Jeffrey BChief Business Officer | SSale | −4.08K | $1.38 | −$5.63K | −4.5%86.6K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Rowland Lloyd AGeneral Counsel | SSale | −4.08K | $1.38 | −$5.63K | −4.0%98.0K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Ogden ChristopherSVP, Finance and Accounting | SSale | −1.99K | $1.38 | −$2.75K | −3.9%48.7K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | Belvin MarciaSVP, Chief Scientific Officer | SSale | −4.12K | $1.30 | −$5.35K | −2.7%148.0K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | Landau Jeffrey BChief Business Officer | SSale | −4.12K | $1.30 | −$5.35K | −5.1%76.4K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | McCarthy Sean A.CEO | SSale | −14.6K | $1.30 | −$19.0K | −3.3%430.8K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | Rowland Lloyd AGeneral Counsel | SSale | −5.49K | $1.30 | −$7.13K | −6.4%80.6K after | |
| Mar 31, 2023 (view filing) | Mar 29 | 2 days | Jones Elaine VDirector | PPurchase | +5.00K | $1.55 | +$7.75K | +3,521.1%5.14K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Ogden ChristopherSVP, Finance and Accounting | SSale | −516 | $1.98 | −$1.02K | −1.3%37.8K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | McCarthy Sean A.CEO | SSale | −7.12K | $1.88 | −$13.4K | −1.8%388.8K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Campoy CarlosChief Financial Officer | SSale | −1.75K | $1.98 | −$3.46K | −4.4%38.2K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Rowland Lloyd AGeneral Counsel | SSale | −2.04K | $1.98 | −$4.03K | −2.8%71.1K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Landau Jeffrey BChief Financial Officer | SSale | −1.48K | $1.98 | −$2.92K | −2.1%69.2K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Peterson Amy C.EVP, Chief Development Officer | SSale | −4.26K | $1.98 | −$8.43K | −6.8%58.4K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Peterson Amy C.EVP, Chief Development Officer | SSale | −7.46K | $1.42 | −$10.6K | −10.6%62.7K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Landau Jeffrey BChief Business Officer | SSale | −4.21K | $1.42 | −$5.97K | −12.0%30.7K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | McCarthy Sean A.President and CEO | SSale | −14.9K | $1.42 | −$21.2K | −4.9%290.9K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Rowland Lloyd AGeneral Counsel | SSale | −5.60K | $1.42 | −$7.95K | −11.4%43.7K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Hannah Alison L.Chief Medical Officer | SSale | −5.60K | $1.42 | −$7.95K | −14.9%31.9K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Campoy CarlosChief Financial Officer | SSale | −3.95K | $1.42 | −$5.61K | −9.0%40.0K after |